PORTERHOUSE INSIGHTS
INSPIRED BY SCIRIS™

BLINDED CASE STUDY

The IgAN Patient Pathway as reported by HCPs

The Challenge

Our client required insights to build a clear and comprehensive understanding of **the IgAN management pathway** and **their asset's opportunity** in this landscape.

To do this we needed to:

01 Map the pathway from diagnosis to ongoing management

02 Understand current treatment algorithms

03 Understand different patient profiles

04 Explore reactions to the TPP and where it would fit in the treatment pathway

**Project also had a patient component*

Our approach

7
markets surveyed & interviewed
Across EU & Nordics

150+
nephrologists completed the questionnaire

40+
follow-up qualitative interviews

300+
IgAN patient record forms collected

The Outcome

Interview and survey insights were combined into a comprehensive picture of the IgAN landscape and the asset's place within it.

The patient pathway (Europe)

PRESENTATION

¾ acute (e.g. haematuria)

¼ non-specific (e.g. hypertension)

DIAGNOSIS

All patients diagnosed with biopsy by a nephrologist

TREATMENT

Most patients (~two-thirds) managed by a nephrologist

Time to reach a nephrologist: **2 weeks – 1 year**

Treatment algorithm fit



Expected fit: 2nd line

Key findings

1. **Expected uptake of the client's drug was high**, aligning with positive feedback on the profile
2. **Uptake was limited by indication**, with HCPs eager to prescribe to patients
3. **The IgAN pathway works quite efficiently**; the client is likely only able to impact biopsy frequency and patient uptake

Planning your next project?
Get in touch with our team to discuss how we can help.
www.porterhouseinsights.com